ArcherDX agrees to acquisition by genetics tester Invitae for up to $1.4B
BOULDER and SAN FRANCISCO — Just weeks after it filed for a $100 million initial public offering, Boulder genomics testing company ArcherDX Inc. is being acquired by Invitae Inc. (NYSE: NVTA).
Invitae will pay $325 million in cash and 30 million shares of its stock to ArcherDX’s investors upon the transaction’s closure, and may issue an additional 27 million shares upon reaching certain milestones. The companies value the deal at up to $1.4 billion.
Invitae stock spiked in early trading Monday, gaining 40.51% to reach $26.29 as of 9:15 a.m. Mountain Time.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Biopharmaceutical company AmideBio LLC has received a $1.93 million grant from the federal government for…
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Boulder’s Human Relations Fund, which supports community-initiated activities that focus on civil rights, human rights…
-
TiFin Group , a Boulder-based financial technology umbrella company, has offloaded its ownership stake in…
